Search results
Results from the WOW.Com Content Network
Donepezil is a centrally acting reversible acetylcholinesterase inhibitor and structurally unrelated to other anticholinesterase agents. [8] [5] Common side effects include nausea, trouble sleeping, aggression, diarrhea, feeling tired, and muscle cramps. [8] [11] Serious side effects may include abnormal heart rhythms, urinary incontinence, and ...
Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. [1] It contains memantine , as the hydrochloride, a NMDA receptor antagonist ; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor . [ 1 ]
Acetylcholine Acetylcholinesterase Acetylcholinesterase inhibition. Acetylcholinesterase inhibitors (AChEIs) also often called cholinesterase inhibitors, [1] inhibit the enzyme acetylcholinesterase from breaking down the neurotransmitter acetylcholine into choline and acetate, [2] thereby increasing both the level and duration of action of acetylcholine in the central nervous system, autonomic ...
Paraoxon and rivastigmine are both acetylcholinesterase inhibitors and butyrylcholinesterase inhibitors. [14] [11] [7]In 2015, the United States Food and Drug Administration's Adverse Event Reporting System database compared rivastigmine to the other ChEI drugs donepezil and galantamine found that rivastigmine was associated with a higher frequency of reports of death as an adverse event.
The sedative effects of cyclobenzaprine are likely due to its antagonistic effect on histamine, serotonin, and muscarinic receptors. [medical citation needed] Agitation is a common side effect observed, especially in the elderly.
Side-effects and ADRs associated with donepezil can be classified in two main categories: common side-effects, most of them observed in clinical trials with AD patients, and unfrequent or extraordinary side-effects, seen in especial conditions or in small clusters of patients with different pathologies under treatment with other concomitant drugs.
The available research seems to suggest that the concurrent prophylactic use of a neuroleptic and an antiparkinsonian drug is useless to avoid early extrapyramidal side-effects and may render the person more sensitive to tardive dyskinesia. Since 1973 the use of these drugs has been found to be associated with the development of tardive dyskinesia.
Celexa – an antidepressant of the SSRI class; Centrax – an anti-anxiety agent; Clozaril – atypical antipsychotic used to treat resistant schizophrenia; Concerta (methylphenidate) – an extended release form of methylphenidate